Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2007-12-6
pubmed:abstractText
Gastric cancer is the second most common cause of cancer deaths worldwide. The identification of molecular genetic parameters that are associated with response to chemotherapy and prognosis is of utmost interest. We examined methylation of the apoptosis-related genes, TMS1 and DAPK, in 81 primary gastric cancers using methylation-specific PCR and compared their methylation status with clinicopathological findings. Aberrant methylation of TMS1 and DAPK genes was detected in 26 (32.1%) tumors and in 18 (22.2%) tumors, respectively. The overall survival of patients with both methylated genes was significantly shorter compared with those with only one methylated gene or no methylated genes (p = 0.0003). Neither gene methylation had any relation to other clinicopathological findings. Next, we examined 43 patients treated by 5-fluorouracil-based chemotherapy, who had distant metastasis or recurrence after radical resection, to determine the relation between chemosensitivity and methylation. The response rate was lower in patients with either methylation than without (TMS1: 22.2% vs. 48.0%; DAPK: 21.4% vs. 44.8%). Overall survival tended to be shorter in the patients with both methylations compared with either or no methylations (p = 0.0806). The time to progression of patients with methylation of TMS1 or DAPK was significantly shorter than patients without methylation (TMS1: p = 0.0123; DAPK: p = 0.0464). Furthermore, the time to progression of patients with both methylated genes was significantly shorter than patients with one methylation or no methylation (p = 0.0082). In conclusion, TMS1 and DAPK methylation might predict the prognosis and response to chemotherapy in gastric cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1097-0215
pubmed:author
pubmed:copyrightInfo
(c) 2007 Wiley-Liss, Inc.
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
122
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
603-8
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:17943730-Adolescent, pubmed-meshheading:17943730-Adult, pubmed-meshheading:17943730-Aged, pubmed-meshheading:17943730-Aged, 80 and over, pubmed-meshheading:17943730-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:17943730-Apoptosis Regulatory Proteins, pubmed-meshheading:17943730-Calcium-Calmodulin-Dependent Protein Kinases, pubmed-meshheading:17943730-Cytoskeletal Proteins, pubmed-meshheading:17943730-DNA Methylation, pubmed-meshheading:17943730-Female, pubmed-meshheading:17943730-Gene Expression Regulation, Neoplastic, pubmed-meshheading:17943730-Humans, pubmed-meshheading:17943730-Male, pubmed-meshheading:17943730-Middle Aged, pubmed-meshheading:17943730-Prognosis, pubmed-meshheading:17943730-Promoter Regions, Genetic, pubmed-meshheading:17943730-Stomach Neoplasms, pubmed-meshheading:17943730-Survival Rate
pubmed:year
2008
pubmed:articleTitle
Methylated TMS1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer.
pubmed:affiliation
Department of Surgical Oncology, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan.
pubmed:publicationType
Journal Article